Defective metabolism of metoprolol in poor hydroxylators of debrisoquine.
Open Access
- 1 August 1982
- journal article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 14 (2), 301-303
- https://doi.org/10.1111/j.1365-2125.1982.tb01982.x
Abstract
Eight healthy volunteers received oral metoprolol 200 mg once daily for a week. The AUC, half-life and duration of beta-adrenoceptor blockade on day 7 was much greater in two subjects than in the remaining six. This suggested that the metabolism of metoprolol was impaired in two and the effect was therefore prolonged. Subsequent testing of oxidation phenotype with oral debrisoquine showed that the subjects with high metoprolol availability were also poor hydroxylators of debrisoquine. The urinary debrisoquine/4-hydroxydebrisoquine ratio was highly correlated with metoprolol AUC, half-life and beta-adrenoceptor blockade at 24 h. Thus patients with a genetic defect in drug oxidation, when treated with metoprolol, are likely to have high plasma concentrations and a prolonged effect.Keywords
This publication has 20 references indexed in Scilit:
- HIGH PLASMA CONCENTRATIONS OF β-RECEPTOR BLOCKING DRUGS AND DEFICIENT DEBRISOQUINE HYDROXYLATIONThe Lancet, 1982
- Impaired oxidation of debrisoquine in patients with perhexiline neuropathy.BMJ, 1982
- Nortriptyline and antipyrine clearance in relation to debrisoquine hydroxylation in manLife Sciences, 1980
- GENETIC IMPAIRMENT OF PHENFORMIN METABOLISMThe Lancet, 1980
- A study of the debrisoquine hydroxylation polymorphism in a Nigerian populationXenobiotica, 1980
- Clinical Pharmacokinetics of MetoprololClinical Pharmacokinetics, 1980
- Pharmacokinetic and Pharmacodynamic Properties of Metoprolol in Patients with Impaired Renal FunctionClinical Pharmacokinetics, 1980
- Polymorphism of carbon oxidation of drugs and clinical implications.BMJ, 1978
- POLYMORPHIC HYDROXYLATION OF DEBRISOQUINEThe Lancet, 1977
- Why hypertensive patients vary in their response to oral debrisoquine.BMJ, 1977